跳至主要内容
临床试验/NCT00931034
NCT00931034已完成不适用

The Effect of South Beach Diet™ Using South Beach Diet™ Products Compared to the American Diabetic Association Diabetes Meal Plan on Body Weight and Satiety in Overweight Diabetic Women

Mondelēz International, Inc.12 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2007年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
120
试验地点
12
主要终点
Change in body weight from baseline to week 24

研究概览

简要总结

The purpose of this study is to examine the effectiveness of the South Beach Diet and products compared to the American Diabetic Association Diabetes Meal Plan.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Female age 18 to 55 years
  • Females of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result
  • Healthy as determined by laboratory results and medical history
  • Waist circumference > 87 cm
  • Stable weight defined as < 4.5 kg gained or lost in past year
  • Agreement to maintain current level of physical activity throughout the study
  • Diagnosed with Type II diabetes mellitus with fasting blood glucose 100 - 250 mg/dl (5.6 - 13.9 mmol/L)
  • Ability to comprehend and complete the questionnaires and forms
  • Agreement to comply with study procedures, test article consumption, and has access to a microwave oven
  • Voluntary, written, informed consent to participate in the study

排除标准

  • Pregnant, breastfeeding, or planning to become pregnant during the course of the trial
  • Use of prescription or over the counter products known to effect weight including but not limited to the following:
  • megestrol acetate;
  • somatropin;
  • sibutramine;
  • orlistat;
  • paroxetine;
  • dextroamphetamine;
  • methylphenidate;
  • atomoxetine;
  • quetiapine;
  • olanzepine;
  • risperidone, within 4 weeks of randomization and during the trial
  • Unstable medication for diabetes mellitus (Dosage must be stable for 90 days prior to randomization), use of insulin is exclusionary
  • Alcohol use > 2 standard alcoholic drinks per day
  • Significant cardiac history defined as a history of:
  • myocardial infarction (MI);
  • coronary angioplasty or bypass graft(s);
  • valvular disease or repair;
  • unstable angina pectoris;
  • transient ischemic attack (TIA);
  • cerebrovascular accidents (CVA);
  • congestive heart failure; or
  • coronary artery disease (CAD)
  • History of or current diagnosis of any cancer (except for successfully treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer in full remission for more than 5 years are acceptable.
  • Uncontrolled hypertension defined as untreated systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg
  • Unstable renal and/or liver disease
  • History of alcohol or drug abuse within the past year
  • Unstable psychiatric disorder requiring hospitalization within the past 6 months
  • Immunocompromised individuals such as subjects that have undergone organ transplantation or subjects diagnosed with human immunodeficiency virus (HIV)
  • History of hemoglobinopathies such as sickle cell anemia or thalassemia, sideroblastic anemia
  • Participation in another clinical research trial within 30 days prior to randomization and during the trial
  • Significant abnormal liver function as defined as AST and/or ALT > 2 x ULN, and/or bilirubin > 2 x ULN
  • Serum creatinine > 125 umol/L
  • Anemia of any etiology defined as hemoglobin < 110 g/L
  • Uncontrolled and/or untreated thyroid disorder
  • Unstable medications (Dosage must be stable for 90 days prior to randomization)
  • History of food allergies or sensitivities, including lactose intolerance
  • Vegetarians
  • Cognitively impaired and/or unable to give informed consent
  • Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject

结局指标

主要结局

Change in body weight from baseline to week 24

时间窗: 24 weeks

次要结局

  • Assess the satiety response to the individual diets(24 weeks)
  • Analyze circumference measurements & body composition; blood glucose, HbA1c, insulin, lipid profile, blood pressure & questionnaire responses on food cravings and quality of life(24 weeks)

研究者

发起方
Mondelēz International, Inc.
申办方类型
Industry

研究点 (12)

Loading locations...

相似试验